RNA interference for human therapy

September 20, 2012
RNA interference for human therapy
Credit: Thinkstock

Leading scientists in the field investigated the potential of RNA interference (RNAi) technology as a therapeutic intervention for down-regulating the expression of disease-associated genes. Project deliverables hold significant exploitation ground in research and medicine.

RNAi has emerged as a powerful technology for down-regulating gene expression, culminating in the Nobel prize award for Medicine in 2006. Research has shown that it could be effectively used in a variety of tissues to knock down – especially those involved in disease – thus demonstrating the potential of RNAi in human therapy.

The EU ' technology as human therapeutic tool' (RIGHT) initiative aimed to explore the technology of RNAi for therapy by delineating its underlying mechanisms. To achieve that, project partners had to overcome key technological barriers such as undesired interferon response and insufficient delivery, stability and targeting of RNAi inhibitors to the appropriate cells.

Selective reagents were generated for efficient delivery of chemically synthesised or vector-expressed siRNAs to cells and tissues of diseased organisms. Cell biology and were used to assess the function and effectiveness of RNAi for the treatment of selected disorders. In particular, scientists showed the so-far unexplored potential of RNAi against influenza, arthritis, HBV and acute (AML) in pre-clinical models.

Furthermore, the improved understanding of the molecular processes associated with RNAi and the naturally occurring microRNAs (miRNAs) is expected to have applications in healthcare, such as for the therapy of .

The RIGHT consortium demonstrated the efficacy of the RNAi technology as a therapeutic tool for many diseases. The knowledge generated will not only impact future research in the field but RNAi-based solutions are expected to get translated into clinical practice.

Explore further: US Patent Office affirms 'Zamore Design Rule' patents

Related Stories

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.